Back to search results

Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome

IsraelCompletedPHASE2

Conditions

Sjögren Syndrome

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Novartis Investigative Site, Duluth, Georgia, United States

  • Novartis Investigative Site, Indianapolis, Indiana, United States

  • Novartis Investigative Site, Baton Rouge, Louisiana, United States

  • Novartis Investigative Site, Baltimore, Maryland, United States

  • Novartis Investigative Site, Boston, Massachusetts, United States

  • Novartis Investigative Site, Mineola, New York, United States

  • Novartis Investigative Site, Philadelphia, Pennsylvania, United States

  • Novartis Investigative Site, Madison, Wisconsin, United States

  • Novartis Investigative Site, Ciudad Autonoma de Bs As, Buenos Aires, Argentina

  • Novartis Investigative Site, CABA, Argentina

  • Novartis Investigative Site, Nedlands, Western Australia, Australia

  • Novartis Investigative Site, Graz, Austria

  • Novartis Investigative Site, Vienna, Austria

  • Novartis Investigative Site, Vitória, Espírito Santo, Brazil

  • Novartis Investigative Site, Juiz de Fora, Minas Gerais, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, Toronto, Ontario, Canada

  • Novartis Investigative Site, Rimouski, Quebec, Canada

  • Novartis Investigative Site, Trois-Rivières, Quebec, Canada

  • Novartis Investigative Site, Valdivia, Los Ríos Region, Chile

  • Novartis Investigative Site, Santiago, RM, Chile

  • Novartis Investigative Site, Concepción, Chile

  • Novartis Investigative Site, Santiago, Chile

  • Novartis Investigative Site, Santiago, Chile

  • Novartis Investigative Site, Medellín, Antioquia, Colombia

  • Novartis Investigative Site, Barranquilla, Atlántico, Colombia

  • Novartis Investigative Site, Cali, Valle del Cauca Department, Colombia

  • Novartis Investigative Site, Brest, France

  • Novartis Investigative Site, Le Kremlin-Bicêtre, France

  • Novartis Investigative Site, Lille, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Strasbourg, France

  • Novartis Investigative Site, Bonn, Germany

  • Novartis Investigative Site, Dresden, Germany

  • Novartis Investigative Site, Freiburg im Breisgau, Germany

  • Novartis Investigative Site, Würzburg, Germany

  • Novartis Investigative Site, Athens, Greece

  • Novartis Investigative Site, Székesfehérvár, Fejér, Hungary

  • Novartis Investigative Site, Budapest, Hungary

  • Novartis Investigative Site, Szeged, Hungary

  • Novartis Investigative Site, Haifa, Israel

  • Novartis Investigative Site, Kfar Saba, Israel

  • Novartis Investigative Site, Ramat Gan, Israel

  • Novartis Investigative Site, Milan, MI, Italy

  • Novartis Investigative Site, Pisa, PI, Italy

  • Novartis Investigative Site, Udine, UD, Italy

  • Novartis Investigative Site, Nagoya, Aichi-ken, Japan

  • Novartis Investigative Site, Sasebo, Nagasaki, Japan

  • Novartis Investigative Site, Kurashiki, Okayama-ken, Japan

  • Novartis Investigative Site, Chuo Ku, Tokyo, Japan

  • Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan

  • Novartis Investigative Site, Groningen, Netherlands

  • Novartis Investigative Site, Rotterdam, Netherlands

  • Novartis Investigative Site, Almada, Portugal

  • Novartis Investigative Site, Lisbon, Portugal

  • Novartis Investigative Site, Lisbon, Portugal

  • Novartis Investigative Site, Ponte de Lima, Portugal

  • Novartis Investigative Site, Brasov, Romania

  • Novartis Investigative Site, Cluj-Napoca, Romania

  • Novartis Investigative Site, Kazan', Russia

  • Novartis Investigative Site, Moscow, Russia

  • Novartis Investigative Site, Orenburg, Russia

  • Novartis Investigative Site, Saint Petersburg, Russia

  • Novartis Investigative Site, Tomsk, Russia

  • Novartis Investigative Site, Yekaterinburg, Russia

  • Novartis Investigative Site, Seoul, Seocho Gu, South Korea

  • Novartis Investigative Site, Stockholm, SE, Sweden

  • Novartis Investigative Site, Ankara, Turkey (Türkiye)

  • Novartis Investigative Site, Birmingham, United Kingdom

  • Novartis Investigative Site, Doncaster, United Kingdom

  • Novartis Investigative Site, Manchester, United Kingdom

Study leads

  • Study Director Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals

View source on ClinicalTrials.gov(opens in a new tab)